前列腺癌骨转移患者的贫血和血小板减少症。
Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases.
机构信息
Department of Internal Medicine - Division of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway.
出版信息
BMC Cancer. 2010 Jun 13;10:284. doi: 10.1186/1471-2407-10-284.
BACKGROUND
The purpose of this study was to determine the incidence, risk factors and prognostic impact of anaemia and thrombocytopenia in patients with bone metastases (BM) from prostate cancer.
METHODS
Retrospective cohort study including 51 consecutive patients treated at a community hospital. Twenty-nine patients (57%) received taxotere after diagnosis of BM.
RESULTS
Haemoglobin (Hb) < or = 12.0 g/dL at BM detection was associated with shorter overall survival. During follow-up, 25 patients (49%) experienced episodes with Hb < 10 g/dL unrelated to side effects of cancer therapy. Fifteen patients required red blood cell transfusion. Median time from diagnosis of BM to Hb < 10 g/dL was 23 months. Median survival from Hb < 10 g/dL was 5.4 months. There was no factor predicting for Hb < 10 g/dL. Five patients (10%) developed thrombocyte (Trc) count <50 x 10(9)/L. All of these had previously received blood transfusion. Median interval from Hb < 10 g/dL to Trc < 50 x 10(9)/L was 2.5 months. Survival after thrombocytopenia was short (3 weeks to 4 months). Haematuria and subdural haematoma were among the causes of death.
CONCLUSIONS
We found high rates of significant bone marrow failure in treatment-refractory patients. Both Hb < 10 g/dL and Trc < 50 x 10(9)/L predict for unfavourable survival.
背景
本研究旨在确定前列腺癌骨转移（BM）患者贫血和血小板减少的发生率、风险因素和预后影响。
方法
回顾性队列研究纳入了在社区医院接受治疗的 51 例连续患者。29 例（57%）在诊断为 BM 后接受了多西紫杉醇治疗。
结果
BM 检测时血红蛋白（Hb）<或=12.0 g/dL 与总生存期缩短相关。在随访期间，25 例患者（49%）经历了与癌症治疗副作用无关的 Hb < 10 g/dL 发作。15 例患者需要输血。从诊断为 BM 到 Hb < 10 g/dL 的中位时间为 23 个月。从 Hb < 10 g/dL 开始的中位生存时间为 5.4 个月。没有因素可以预测 Hb < 10 g/dL。5 例患者（10%）血小板（Trc）计数<50 x 10(9)/L。所有这些患者之前都接受过输血。从 Hb < 10 g/dL 到 Trc < 50 x 10(9)/L 的中位间隔为 2.5 个月。血小板减少后的生存时间较短（3 周至 4 个月）。血尿和硬膜下血肿是死亡的原因之一。
结论
我们发现治疗抵抗患者骨髓衰竭发生率较高。Hb < 10 g/dL 和 Trc < 50 x 10(9)/L 均预测预后不良。
Zotero 插件